NASDAQ:TECH - Bio-Techne Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $352.30
  • Forecasted Upside: -2.60 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$361.69
▼ -3.37 (-0.92%)
1 month | 3 months | 12 months
Get New Bio-Techne Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TECH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TECH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$352.30
▼ -2.60% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for Bio-Techne in the last 3 months. The average price target is $352.30, with a high forecast of $440.00 and a low forecast of $220.00. The average price target represents a -2.60% upside from the last price of $361.69.
Buy
The current consensus among 10 contributing investment analysts is to buy stock in Bio-Techne. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/6/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/5/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/4/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/2/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
8/31/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/29/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/28/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2021Stifel NicolausUpgradeHold ➝ Buy$435.00Low
i
2/3/2021CitigroupBoost Price TargetNeutral$310.00 ➝ $400.00Low
i
2/3/2021Craig HallumBoost Price TargetBuy$352.00 ➝ $440.00Medium
i
1/25/2021BenchmarkBoost Price TargetBuy$320.00 ➝ $410.00Low
i
11/9/2020KeyCorpInitiated CoverageSector Weight ➝ Sector Weight$340.00Low
i
11/6/2020Robert W. BairdBoost Price TargetOutperform$289.00 ➝ $320.00Low
i
11/6/2020SVB LeerinkBoost Price TargetOutperform$285.00 ➝ $320.00Low
i
9/30/2020Atlantic SecuritiesInitiated CoverageOverweight$365.00Low
i
8/5/2020SVB LeerinkBoost Price TargetOutperform$265.00 ➝ $285.00Medium
i
8/4/2020Wells Fargo & CompanyReiterated RatingHoldMedium
i
8/4/2020Craig HallumUpgradeHold ➝ Buy$211.00 ➝ $328.00Medium
i
7/15/2020StephensDowngradeOverweight ➝ Equal Weight$253.00 ➝ $273.00High
i
6/18/2020CitigroupBoost Price TargetNeutral$230.00 ➝ $260.00Low
i
5/27/2020Stifel NicolausDowngradeBuy ➝ Hold$245.00 ➝ $260.00Medium
i
5/14/2020BenchmarkInitiated CoverageBuy$290.00Low
i
5/1/2020StephensBoost Price TargetOverweight$230.00 ➝ $253.00High
i
5/1/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$190.00 ➝ $220.00High
i
5/1/2020Stifel NicolausBoost Price TargetBuy$210.00 ➝ $245.00Medium
i
4/20/2020CitigroupBoost Price TargetNeutral$175.00 ➝ $215.00Low
i
4/20/2020Craig HallumLower Price TargetBuy$218.00 ➝ $211.00Medium
i
4/2/2020Stifel NicolausLower Price TargetBuy$235.00 ➝ $210.00Medium
i
3/30/2020Wells Fargo & CompanyLower Price TargetEqual Weight$225.00 ➝ $190.00High
i
3/20/2020CitigroupLower Price TargetNeutral$225.00 ➝ $175.00High
i
2/24/2020Eight CapitalDowngradeBuy ➝ NeutralLow
i
2/5/2020Robert W. BairdBoost Price TargetOutperform$222.00 ➝ $230.00Low
i
2/5/2020CitigroupLower Price TargetNeutral$235.00 ➝ $225.00Low
i
1/8/2020StephensInitiated CoverageOverweightLow
i
1/7/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$230.00Low
i
1/6/2020CitigroupInitiated CoverageNeutral$235.00Low
i
11/14/2019Stifel NicolausInitiated CoverageBuy$235.00High
i
9/26/2019SVB LeerinkReiterated RatingOutperform$230.00 ➝ $240.00Low
i
7/2/2019Janney Montgomery ScottUpgradeNeutral ➝ Buy$200.00 ➝ $270.00High
i
3/4/2019ArgusReiterated RatingBuyMedium
i
2/5/2019Craig HallumReiterated RatingHold$154.00 ➝ $179.00Low
i
Rating by Alexander Nowak at Craig Hallum
1/14/2019StephensUpgradeEqual Weight ➝ Overweight$180.00Low
i
11/30/2018The Goldman Sachs GroupSet Price TargetHold$165.00Low
i
Rating by Patrick B Donnelly at The Goldman Sachs Group, Inc.
10/31/2018Craig HallumDowngradeBuy ➝ Hold$215.00 ➝ $154.00Medium
i
10/17/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$190.00Medium
i
10/2/2018ArgusBoost Price TargetBuy ➝ Buy$210.00 ➝ $230.00Low
i
8/9/2018CitigroupBoost Price TargetBuy ➝ Buy$160.00 ➝ $205.00Low
i
8/8/2018Craig HallumBoost Price TargetBuy$160.00 ➝ $215.00Medium
i
8/8/2018Robert W. BairdBoost Price TargetOutperform ➝ Positive$162.00 ➝ $191.00Medium
i
8/8/2018SVB LeerinkSet Price TargetOutperform$160.00 ➝ $190.00Medium
i
Rating by Puneet Souda at SVB Leerink LLC
6/27/2018Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$165.00High
i
Rating by Dan Leonard at Deutsche Bank Aktiengesellschaft
6/15/2018ArgusInitiated CoverageBuy$185.00Medium
i
5/3/2018Deutsche Bank AktiengesellschaftLower Price TargetBuy ➝ Buy$167.00 ➝ $165.00High
i
Rating by Dan Leonard at Deutsche Bank Aktiengesellschaft
5/3/2018SVB LeerinkSet Price TargetBuy$151.00 ➝ $160.00Low
i
Rating by Puneet Souda at SVB Leerink LLC
3/1/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy ➝ Buy$154.00 ➝ $163.00Low
i
Rating by Dan Leonard at Deutsche Bank Aktiengesellschaft
2/7/2018Craig HallumReiterated RatingBuy$140.00 ➝ $160.00Medium
i
2/7/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$154.00 ➝ $157.00Medium
i
1/18/2018Robert W. BairdReiterated RatingBuy$154.00Low
i
12/5/2017SVB LeerinkReiterated RatingBuyMedium
i
Rating by Puneet Souda at SVB Leerink LLC
10/31/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$145.00N/A
i
Rating by Dan Leonard at Deutsche Bank Aktiengesellschaft
10/24/2017CitigroupReiterated RatingBuy$125.00 ➝ $115.00N/A
i
8/30/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$132.00Medium
i
Rating by Dan Leonard at Deutsche Bank Aktiengesellschaft
8/9/2017Deutsche Bank AktiengesellschaftBoost Price TargetBuy$130.00 ➝ $132.00Low
i
7/13/2017Wells Fargo & CompanyInitiated CoverageMarket Perform ➝ Market PerformLow
i
5/3/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$115.00 ➝ $122.00Low
i
5/3/2017CitigroupReiterated RatingBuy$115.00 ➝ $125.00Low
i
3/27/2017Janney Montgomery ScottDowngradeBuy ➝ NeutralHigh
i
2/9/2017CitigroupInitiated CoverageBuy$115.00N/A
i
1/18/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$115.00N/A
i
11/10/2016SVB LeerinkInitiated CoverageOutperform$122.00N/A
i
Rating by Dan Leonard at SVB Leerink LLC
8/18/2016Robert W. BairdBoost Price TargetOutperform$115.00 ➝ $116.00N/A
i
7/10/2016SVB LeerinkReiterated RatingHoldN/A
i
Rating by Dan Leonard at SVB Leerink LLC
5/5/2016SVB LeerinkReiterated RatingHold$105.00N/A
i
5/3/2016Janney Montgomery ScottUpgradeNeutral ➝ Buy$100.00 ➝ $118.00N/A
i
(Data available from 2/27/2016 forward)
Bio-Techne logo
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Read More

Today's Range

Now: $361.69
$358.98
$368.45

50 Day Range

MA: $362.84
$318.43
$411.00

52 Week Range

Now: $361.69
$155.17
$414.99

Volume

245,717 shs

Average Volume

194,645 shs

Market Capitalization

$14.03 billion

P/E Ratio

57.87

Dividend Yield

0.35%

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Bio-Techne?

The following Wall Street analysts have issued stock ratings on Bio-Techne in the last year: Atlantic Securities, Benchmark Co., Citigroup Inc., Craig Hallum, KeyCorp, Robert W. Baird, Stephens, Stifel Nicolaus, SVB Leerink LLC, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for TECH.

What is the current price target for Bio-Techne?

10 Wall Street analysts have set twelve-month price targets for Bio-Techne in the last year. Their average twelve-month price target is $352.30, suggesting a possible downside of 2.6%. Craig Hallum has the highest price target set, predicting TECH will reach $440.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $220.00 for Bio-Techne in the next year.
View the latest price targets for TECH.

What is the current consensus analyst rating for Bio-Techne?

Bio-Techne currently has 4 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TECH will outperform the market and that investors should add to their positions of Bio-Techne.
View the latest ratings for TECH.

What other companies compete with Bio-Techne?

How do I contact Bio-Techne's investor relations team?

Bio-Techne's physical mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company's listed phone number is 612-379-8854 and its investor relations email address is [email protected] The official website for Bio-Techne is www.bio-techne.com.